Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade ...

How Twist’s New Preclinical-Grade Plasmid DNA Preps Could Reshape the TWST Nucleic Acid Therapeutics Story

In early December 2025, Twist Bioscience launched research-grade Plasmid DNA Preps with animal origin-free and endotoxin-free options tailored to stringent preclinical study requirements. This move ...
Benzinga.com

Earnings Outlook For Twist Bioscience

Twist Bioscience (NASDAQ:TWST) will release its quarterly earnings report on Friday, 2025-11-14. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Twist Bioscience ...
SFGate

Twist Bioscience: Fiscal Q4 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Twist Bioscience Corp. (TWST) on Friday reported a loss of $27.1 million in its fiscal fourth quarter. On a per-share basis, the ...

A 'renter’s market' allowed this CEO to bring everyone together for less

"It's kind of a renter’s market right now," Twist CEO Emily Leproust told the Business Times while striking a deal to ...
Morningstar

Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ...
Insider Monkey

Is Twist Bioscience Corporation (TWST) a Compelling Risk-Regarded Opportunity?

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equities continue to ...